Lista de obras -

Antiretroviral combinations implicated in emergence of the L74I and L74V resistance mutations in HIV-1-infected patients

artículo científico publicado en 2009

Association of Gag cleavage sites to protease mutations and to virological response in HIV-1 treated patients

artículo científico publicado en 2006

Clinically relevant interpretation of genotype and relationship to plasma drug concentrations for resistance to saquinavir-ritonavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients

artículo científico publicado en 2004

Clonal analyses of HIV quasispecies in patients harbouring plasma genotype with K65R mutation associated with thymidine analogue mutations or L74V substitution

artículo científico publicado en 2005

Combination of two pathways involved in raltegravir resistance confers dolutegravir resistance

artículo científico publicado en 2015

Comparison of the dynamics of resistance-associated mutations to nucleoside reverse transcriptase inhibitors, nonnucleoside reverse transcriptase inhibitors, and protease inhibitors after cessation of antiretroviral combination therapy.

artículo científico publicado en 2004

Differential impact of APOBEC3-driven mutagenesis on HIV evolution in diverse anatomical compartments

artículo científico publicado en 2014

E138K and M184I mutations in HIV-1 reverse transcriptase coemerge as a result of APOBEC3 editing in the absence of drug exposure

artículo científico publicado en 2012

E17A mutation in HIV-1 Vpr confers resistance to didanosine in association with thymidine analog mutations

artículo científico publicado en 2011

Factors associated with proviral DNA HIV-1 tropism in antiretroviral therapy-treated patients with fully suppressed plasma HIV viral load: implications for the clinical use of CCR5 antagonists

artículo científico publicado en 2010

Factors associated with the selection of mutations conferring resistance to protease inhibitors (PIs) in PI-experienced patients displaying treatment failure on darunavir

artículo científico publicado en 2007

Genotypic inhibitory quotient as predictor of virological response to ritonavir-amprenavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients

artículo científico publicado en 2003

Highly multidrug-resistant HIV: clonal analysis and therapeutic strategies

artículo científico publicado en 2013

Historical HIV-RNA resistance test results are more informative than proviral DNA genotyping in cases of suppressed or residual viraemia

artículo científico

INSTI-Based Triple Regimens in Treatment-Naïve HIV-Infected Patients Are Associated With HIV-RNA Viral Load Suppression at Ultralow Levels

article

Identification of a rare mutation at reverse transcriptase Lys65 (K65E) in HIV-1-infected patients failing on nucleos(t)ide reverse transcriptase inhibitors

artículo científico publicado en 2013

Impact of gag mutations on selection of darunavir resistance mutations in HIV-1 protease

artículo científico publicado en 2008

Improved detection of resistance at failure to a tenofovir, emtricitabine and efavirenz regimen by ultradeep sequencing

artículo científico publicado en 2015

Interruption of nonnucleoside reverse transcriptase inhibitor (NNRTI) therapy for 2 months has no effect on levels of human immunodeficiency virus type 1 in plasma of patients harboring viruses with mutations associated with resistance to NNRTIs

artículo científico publicado en 2003

Less frequent follow-up in routine care than in trials does not impact resistance selection in patients failing DRV/r or ATV/r first line treatment

artículo científico publicado en 2014

Low frequency of HIV-1 tropism evolution in patients successfully treated for at least 2 years

article

Low-level HIV-1 viraemia in patients on HAART: risk factors and management in clinical practice

artículo científico publicado en 2015

Multicenter comparison of the new Cobas 6800 system with Cobas Ampliprep/Cobas TaqMan and Abbott RealTime for the quantification of HIV, HBV and HCV viral load

artículo científico publicado en 2017

Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro

artículo científico publicado en 2008

National sentinel surveillance of transmitted drug resistance in antiretroviral-naive chronically HIV-infected patients in France over a decade: 2001-2011.

artículo científico publicado en 2013

New HIV-1 circulating recombinant form 94: from phylogenetic detection of a large transmission cluster to prevention in the age of geosocial-networking apps in France, 2013 to 2017

scientific article published on 01 September 2019

New resistance mutations to nucleoside reverse transcriptase inhibitors at codon 184 of HIV-1 reverse transcriptase (M184L and M184T)

scientific article published on 27 November 2018

Partially active HIV-1 Vif alleles facilitate viral escape from specific antiretrovirals

artículo científico publicado en 2010

Positive impact of HIV-1 gag cleavage site mutations on the virological response to darunavir boosted with ritonavir

artículo científico publicado en 2011

Prevalence of HIV-1 drug resistance in treated patients with viral load >50 copies/mL in 2009: a French nationwide study

artículo científico publicado en 2013

Prevalence of resistance mutations related to integrase inhibitor S/GSK1349572 in HIV-1 subtype B raltegravir-naive and -treated patients

article

Primary genotypic resistance of HIV-1 to the maturation inhibitor PA-457 in protease inhibitor-experienced patients

artículo científico publicado en 2007

Quasispecies variant dynamics during emergence of resistance to raltegravir in HIV-1-infected patients

artículo científico publicado en 2009

Raltegravir has no residual antiviral activity in vivo against HIV-1 with resistance-associated mutations to this drug

artículo científico publicado en 2009

Resistance mutations before and after tenofovir regimen failure in HIV-1 infected patients

artículo científico publicado en 2005

Resistance profiles observed in virological failures after 24 weeks of amprenavir/ritonavir containing regimen in protease inhibitor experienced patients

artículo científico publicado en 2004

Resistance-associated mutations to etravirine (TMC-125) in antiretroviral-naïve patients infected with non-B HIV-1 subtypes

artículo científico publicado en 2009

Risk factors for selection of the L74I reverse transcriptase mutation in human immunodeficiency virus type 1-infected patients

artículo científico publicado en 2006

Role of HIV-1 minority populations on resistance mutational pattern evolution and susceptibility to protease inhibitors

artículo científico publicado en 2006

Similar evolution of cellular HIV-1 DNA level in darunavir/ritonavir monotherapy versus triple therapy in MONOI-ANRS136 trial over 96 weeks

artículo científico publicado en 2012

The HIV-1 integrase G118R mutation confers raltegravir resistance to the CRF02_AG HIV-1 subtype.

artículo científico publicado en 2011

Thymidine analogue reverse transcriptase inhibitors resistance mutations profiles and association to other nucleoside reverse transcriptase inhibitors resistance mutations observed in the context of virological failure

artículo científico publicado en 2004

Ultradeep sequencing detection of the R263K integrase inhibitor drug resistance mutation

artículo científico publicado en 2017

Very early ART resulting in the absence of HIV-1 antibodies and in a sustained undetectable plasma HIV-1-RNA and proviral-DNA in an HLA-B*5701 and Δ32 heterozygote HIV-1-infected patient was not associated with functional cure

artículo científico publicado en 2014

Virologic outcome after switching from a nucleoside reverse transcriptase inhibitor to tenofovir in patients with undetectable HIV-1 RNA plasma level

artículo científico publicado en 2004

Lista de obras de

Antiretroviral combinations implicated in emergence of the L74I and L74V resistance mutations in HIV-1-infected patients

Association of Gag cleavage sites to protease mutations and to virological response in HIV-1 treated patients

Clinically relevant interpretation of genotype and relationship to plasma drug concentrations for resistance to saquinavir-ritonavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients

Clonal analyses of HIV quasispecies in patients harbouring plasma genotype with K65R mutation associated with thymidine analogue mutations or L74V substitution

Combination of two pathways involved in raltegravir resistance confers dolutegravir resistance

Comparison of the dynamics of resistance-associated mutations to nucleoside reverse transcriptase inhibitors, nonnucleoside reverse transcriptase inhibitors, and protease inhibitors after cessation of antiretroviral combination therapy.

Differential impact of APOBEC3-driven mutagenesis on HIV evolution in diverse anatomical compartments

E138K and M184I mutations in HIV-1 reverse transcriptase coemerge as a result of APOBEC3 editing in the absence of drug exposure

E17A mutation in HIV-1 Vpr confers resistance to didanosine in association with thymidine analog mutations

Factors associated with proviral DNA HIV-1 tropism in antiretroviral therapy-treated patients with fully suppressed plasma HIV viral load: implications for the clinical use of CCR5 antagonists

Factors associated with the selection of mutations conferring resistance to protease inhibitors (PIs) in PI-experienced patients displaying treatment failure on darunavir

Genotypic inhibitory quotient as predictor of virological response to ritonavir-amprenavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients

Highly multidrug-resistant HIV: clonal analysis and therapeutic strategies

Historical HIV-RNA resistance test results are more informative than proviral DNA genotyping in cases of suppressed or residual viraemia

INSTI-Based Triple Regimens in Treatment-Naïve HIV-Infected Patients Are Associated With HIV-RNA Viral Load Suppression at Ultralow Levels

Identification of a rare mutation at reverse transcriptase Lys65 (K65E) in HIV-1-infected patients failing on nucleos(t)ide reverse transcriptase inhibitors

Impact of gag mutations on selection of darunavir resistance mutations in HIV-1 protease

Improved detection of resistance at failure to a tenofovir, emtricitabine and efavirenz regimen by ultradeep sequencing

Interruption of nonnucleoside reverse transcriptase inhibitor (NNRTI) therapy for 2 months has no effect on levels of human immunodeficiency virus type 1 in plasma of patients harboring viruses with mutations associated with resistance to NNRTIs

Less frequent follow-up in routine care than in trials does not impact resistance selection in patients failing DRV/r or ATV/r first line treatment

Low frequency of HIV-1 tropism evolution in patients successfully treated for at least 2 years

Low-level HIV-1 viraemia in patients on HAART: risk factors and management in clinical practice

Multicenter comparison of the new Cobas 6800 system with Cobas Ampliprep/Cobas TaqMan and Abbott RealTime for the quantification of HIV, HBV and HCV viral load

Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro

National sentinel surveillance of transmitted drug resistance in antiretroviral-naive chronically HIV-infected patients in France over a decade: 2001-2011.

New HIV-1 circulating recombinant form 94: from phylogenetic detection of a large transmission cluster to prevention in the age of geosocial-networking apps in France, 2013 to 2017

New resistance mutations to nucleoside reverse transcriptase inhibitors at codon 184 of HIV-1 reverse transcriptase (M184L and M184T)

Partially active HIV-1 Vif alleles facilitate viral escape from specific antiretrovirals

Positive impact of HIV-1 gag cleavage site mutations on the virological response to darunavir boosted with ritonavir

Prevalence of HIV-1 drug resistance in treated patients with viral load >50 copies/mL in 2009: a French nationwide study

Prevalence of resistance mutations related to integrase inhibitor S/GSK1349572 in HIV-1 subtype B raltegravir-naive and -treated patients

Primary genotypic resistance of HIV-1 to the maturation inhibitor PA-457 in protease inhibitor-experienced patients

Quasispecies variant dynamics during emergence of resistance to raltegravir in HIV-1-infected patients

Raltegravir has no residual antiviral activity in vivo against HIV-1 with resistance-associated mutations to this drug

Resistance mutations before and after tenofovir regimen failure in HIV-1 infected patients

Resistance profiles observed in virological failures after 24 weeks of amprenavir/ritonavir containing regimen in protease inhibitor experienced patients

Resistance-associated mutations to etravirine (TMC-125) in antiretroviral-naïve patients infected with non-B HIV-1 subtypes

Risk factors for selection of the L74I reverse transcriptase mutation in human immunodeficiency virus type 1-infected patients

Role of HIV-1 minority populations on resistance mutational pattern evolution and susceptibility to protease inhibitors

Similar evolution of cellular HIV-1 DNA level in darunavir/ritonavir monotherapy versus triple therapy in MONOI-ANRS136 trial over 96 weeks

The HIV-1 integrase G118R mutation confers raltegravir resistance to the CRF02_AG HIV-1 subtype.

Thymidine analogue reverse transcriptase inhibitors resistance mutations profiles and association to other nucleoside reverse transcriptase inhibitors resistance mutations observed in the context of virological failure

Ultradeep sequencing detection of the R263K integrase inhibitor drug resistance mutation

Very early ART resulting in the absence of HIV-1 antibodies and in a sustained undetectable plasma HIV-1-RNA and proviral-DNA in an HLA-B*5701 and Δ32 heterozygote HIV-1-infected patient was not associated with functional cure

Virologic outcome after switching from a nucleoside reverse transcriptase inhibitor to tenofovir in patients with undetectable HIV-1 RNA plasma level